McAdam LLC’s Kindred Biosciences, Inc. KIN Stock Holding History

McAdam LLC’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,000	Closed	-$26K	–	689
2018 Q3	$26K	Buy	+2,000	New	+$27.1K	0.01%	226

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

McAdam LLC's KIN Position: Q4 2018 in Review

McAdam LLC sold out of Kindred Biosciences, Inc. (KIN) in Q4 2018, closing a stake of 2,000 shares — an estimated $26K sold.

McAdam LLC first reported a position in KIN in Q3 2018 and held it in 1 quarter. The position peaked at $26K in Q3 2018. 72 funds tracked by Wall St. Rank hold KIN as of Q4 2018.

McAdam LLC reported no remaining Kindred Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 2,000 Kindred Biosciences, Inc. shares in Q4 2018, an estimated $26K.
McAdam LLC first reported a position in Kindred Biosciences, Inc. in Q3 2018 and held it in 1 quarter.
McAdam LLC's Kindred Biosciences, Inc. position peaked at $26K in Q3 2018.
72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.